The guidelines on AD proposed by NIA-AA define the biomarkers for early diagnosis of AD as A/T/N regimens, including Aβ42, total Tau, phosphorylated Tau in cerebrospinal fluid, and the detected value of Aβ42 and Tau by PET CT (Scheltens et al., 2016; Jack et al., 2018). This evidence concerns the gene MAPT and Alzheimer disease.